Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds.
暂无分享,去创建一个
Thierry Kogej | Sorel Muresan | Ola Engkvist | Christian Tyrchan | Niklas Blomberg | S. Muresan | N. Blomberg | O. Engkvist | C. Tyrchan | T. Kogej
[1] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[2] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[3] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[4] Michal Vieth,et al. Dependence of molecular properties on proteomic family for marketed oral drugs. , 2006, Journal of medicinal chemistry.
[5] Sorel Muresan,et al. Complementarity between public and commercial databases: new opportunities in medicinal chemistry informatics. , 2007, Current topics in medicinal chemistry.
[6] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[7] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[8] P. Labute. A widely applicable set of descriptors. , 2000, Journal of molecular graphics & modelling.
[9] C. Lipinski. Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.
[10] J. Proudfoot,et al. The evolution of synthetic oral drug properties. , 2005, Bioorganic & medicinal chemistry letters.